


## VALUATION MULTIPLES

**Forward EV / EBITDA Multiples (monthly to 30/06/2020)** Source: FactSet Research Systems Inc.

Multiples in the Healthcare sector have increased over the period. At the end of June, the sector traded on a forward EV / EBITDA multiple of 12.9x, compared to the ASX200 on 10.7x.



**Average Values and Trading Multiples (values as at 28/07/2020)** Source: FactSet Research Systems Inc.

Subsector	Enterprise Value (\$ m)	EV/EBITDA FY2020	EV/EBIT FY2020	Price / Earnings FY2020
Aged Care	1,553	7.4x	15.7x	18.7x
Biotech	135,162	29.8x	34.3x	42.4x
Hospitals & Clinics	48,991	12.8x	21.6x	25.1x
Medical Devices	11,442	32.5x	41.6x	56.0x
<b>Healthcare</b>	<b>202,262</b>	<b>15.5x</b>	<b>24.6x</b>	<b>28.2x</b>

Note: Multiples are based on the forward year of the unreported period, which for the majority of companies in the sector is FY2020. Difference in forward EV/EBITDA multiples between Figure and Table are representative of the timing difference between month-end result, and current day result. Composition of companies in Sector Dashboards are updated every 6 months. Most recent update: February 2020.

## MERGER & ACQUISITION NEWS...



Value: Undisclosed



Australian-based **Genesis Capital** has acquired **SAI Home & Community Care** is an Australian-based company providing community care services to senior citizens and people with disability.



Value: \$40m (49% stake)



**Medibank Private**, an Australia-based health insurance provider, is believed to have paid AUD 40m to acquire a 49% stake in **East Sydney Private Hospital**. The deal represents a return to hospital ownership by an Australian health insurer, with Medibank Private commenting that it could pursue other acquisitions as COVID-19 strains private hospitals. Insurers are thought to be looking to buy hospitals in order to lower medical insurance costs for clients.



Value: Undisclosed

**ECH**, an Australia-based aged care services business, has acquired **Billy**, an Australian health tech company, for an undisclosed price. ECH invested AUD 5m into Billy in November 2018.

## UNDER THE MICROSCOPE...

- **Australian Clinical Labs'** owner, **Crescent Capital**, was thought to be working on a plan to sell part of the operation to **Healius** [ASX:HLS] and part to **Sonic Healthcare** [ASX:SHL]. However, the potential deal may not be likely to receive Australian Competition and Consumer Commission (ACCC) clearance. Private equity is among the likely buyers.
- **AllVascular**, an Australian medical device business, intends to pursue an ASX listing in the second half of next year.
- **Abano Healthcare** [NZE:ABA], an Australian and New Zealand dentist business, is believed to be seeking a private equity investor to back an equity raising, the company is seeking equity to repay an AUD 150m loan. It was noted that BGH Capital had agreed to buy Abano before the emergence of COVID-19 and has returned over the last six weeks with new offers. However, the report said that BGH's latest proposals were not as valuable and have been rejected by the target's board.
- **Glytherix**, an unlisted public Australian immuno-oncology company, is actively seeking AUD 7m (USD 5m) in a Series A equity round, after securing up to AUD 6m in non-dilutive funding.
- **Captix Biomedical**, a privately owned, Australian biomedical technology company that is developing a therapeutic strategy for Type 1 diabetes, is seeking AUD 2.5m for its 30% stake.
- **Proteomics International**, a Perth-based Australian diagnostics company, could attract suitors as it reaches development milestones and gears for commercialization deals for its PromarkerD diabetic kidney disease test.
- **Regis Healthcare's** property assets could make it an enticing takeover target.
- **Firebrick Pharma**, an Australian biotech business, could list on the ASX next year between July 2021 and December 2022 and has launched a pre-IPO funding round.
- **4DMedical**, an Australian developer of non-invasive respiratory imaging solutions, seeks to raise AUD 55.79m through an initial public offering of its ordinary shares on the ASX.
- **Keppel Infrastructure** is said to be the leading contender to buy **Healthscope's** New Zealand pathology business.

## CONTACT DETAILS

If you are interested in specific information regarding mergers and acquisitions in the Healthcare sector, please contact David Hassum or Michael Kakanis.

Name	Position	Phone	Email
Sharon Doyle	Executive Chair	(07) 3218 9122	<a href="mailto:sdoyle@interfinancial.com.au">sdoyle@interfinancial.com.au</a>
Paul Keehan	Non-Executive Director	(07) 3218 9100	<a href="mailto:pkeehan@interfinancial.com.au">pkeehan@interfinancial.com.au</a>
Ted Marchant	Non-Executive Director	(07) 3218 9100	<a href="mailto:tmarchant@interfinancial.com.au">tmarchant@interfinancial.com.au</a>
Mark Steinhardt	Head of M&A	(07) 3218 9105	<a href="mailto:msteinhardt@interfinancial.com.au">msteinhardt@interfinancial.com.au</a>
Brad Shaw	Director – M&A	(07) 3218 9100	<a href="mailto:bshaw@interfinancial.com.au">bshaw@interfinancial.com.au</a>
Brent Wall	Director – M&A	(07) 3218 9102	<a href="mailto:bwall@interfinancial.com.au">bwall@interfinancial.com.au</a>
David Hassum	Director	(07) 3218 9108	<a href="mailto:dhassum@interfinancial.com.au">dhassum@interfinancial.com.au</a>
Andrew Wheeler	Director	(07) 3218 9107	<a href="mailto:awheeler@interfinancial.com.au">awheeler@interfinancial.com.au</a>
Michael Kakanis	Associate	(07) 3218 9106	<a href="mailto:mkakanis@interfinancial.com.au">mkakanis@interfinancial.com.au</a>
Lachlan O'Rourke	Analyst	(07) 3218 9104	<a href="mailto:lorourke@interfinancial.com.au">lorourke@interfinancial.com.au</a>

## DISCLAIMER

This information has been sourced from the ASX, Mergermarket.com and various other public information sources. Forecasts are consensus forecasts sourced from FactSet Research Systems Inc.

**Important Disclaimer** – This may affect your legal rights: Because this document has been prepared without consideration of any specific person's financial situation, particular needs and investment objectives, a financial services licensee or investment adviser should be consulted before any investment decision is made. While this document is based on information from sources which are considered reliable, InterFinancial, its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information contained in this document is complete or accurate. Nor does InterFinancial accept any responsibility to inform you of any matter that subsequently comes to notice, which may affect any of the information contained in this document. This document is a private communication to clients and is not intended for public circulation or for the use of any third party, without the prior approval of InterFinancial. This report does not constitute advice to any person.

**Disclosure.** InterFinancial has no interest in any of the securities mentioned in this publication. However, its directors, executives or consultants may have an interest in some of the securities, directly or indirectly, which are mentioned.

*InterFinancial is a member of Clairfield International, an international corporate finance firm that provides advisory services in crossborder mergers and acquisitions. Clairfield is represented by over 400 people across 22 countries, closing over 100 transactions each year.*

<p><b>InterFinancial</b> Corporate Finance Limited ABN: 49 136 962 966 AFSL: 341675 Level 2, 201 Charlotte Street GPO Box 975 Brisbane Queensland 4001 (07) 3218 9100 admin@interfinancial.com.au www.interfinancial.com.au</p>	
---	---